Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team's extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/24 | $120,000,000 | Series C |
3H Health Investment Bain Capital Life Sciences  Elikon Venture Janus Henderson Investors Legend Capital OrbiMed Advisors Yonghua Capital | undisclosed |
